• securing alternative supplier for yttrium-90 phosphate particle production
One key aspect of managing a company is identifying and mitigating potential future risks. In that context, evolving away from single-source production of the primary components of IsoPet/RadioGel is a strategic objective.
Last year we developed two alternate suppliers for the polymer that is used to produce the hydrogel component. This year we are focusing on the more difficult task of locating a second supplier for our yttrium-90 phosphate particles.
Mike Korenko, Sc.D • CEO • President
We have signed a letter of intent and a non-disclosure agreement with Eckert and
Ziegler to determine if forming a business relationship is in both companies’ best interests. E&Z has an excellent reputation for providing radioactive products for other
clients. They currently supply our yttrium-90 so expanding their role could reduce the shipping cost and logistic issues.
Eckert & Ziegler has assessed our proprietary production procedures and this week their representative observed a full production run at IsoTherapeutics, our current component supplier. It is important to analyze the production requirements and business aspects in detail. We anticipate that this thorough analysis will take considerable time. This is necessary to create a long-term relationship.
Thank you.
Mike Korenko, Sc. D.
CEO • President | Vivos Inc.
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 (90Y) phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB: RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
